A 80-year-old woman with B-cell prolymphocytic leukemia

Alparslan Merdin,¹ Jale Yildiz,¹ Mehmet Sinan Dal,¹ Merih Kızıl Çakar,¹ Hikmetullah Batğlı,¹ Emre Tekgündüz,¹ Aykut Onursever,² Feyzi Altuntas¹

¹Hematology Clinic and Bone Marrow Transplantation Unit, and ²Pathology Clinic, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey

Abstract

Prolymphocytic leukemia (PLL) is a rare subtype of lymphocytic leukemias and its cells are immature lymphocytes. It is divided into 2 subgroups: T-PLL and B-PLL according to the lymphocytic origin of the cells. Discriminating B-PLL from other diseases with clinically-similar features is important because of the different treatment approaches and follow-up programs. Hereby, we report a 80-year-old woman presenting with fatigue, leucocytosis, and mild anemia. Her peripheral blood smear revealed 85% prolymphocytes with moderately condensed nuclear chromatin, prominent nucleoli, and a faintly basophilic cytoplasm. Positron emission tomography-computed tomography showed mediastinal lymph nodes with cervical lymph nodes. There was no pathological FDG involvement in the spleen. Bone marrow aspiration smear exhibited typical wide lymphocytes with prominent nucleoli and abundant agranular cytoplasm. Flow cytometry analysis revealed positive CD5⁺, CD19⁺, CD20⁺, CD22⁺, CD11c⁺, CD25⁺, CD79a⁺ and CD79b⁺. Fluorescence in situ hybridization technique analysis revealed no t(11;14). Bone marrow biopsy revealed interstitially distributed atypical cells with wide nucleus and prominent nucleolus.

Introduction

Prolymphocytic leukemia (PLL) cells are immature lymphocytes. And PLL is a rare subtype of lymphocytic leukemias. PLL is divided into two subgroups. The first is T-PLL and the second is B-PLL according to the lymphocytic origin of the PLL cells. T-PLL cells have CD2⁺, CD3⁺, CD5⁺, CD7⁺ cell surface markers. On the other side, B-PLL cells have CD19⁺ and CD20⁺ on the cells. 55% or more prolymphocytes circulating indicates prolymphocytic leukemia. This ratio is used in differentiating B-PLL from chronic lymphocytic leukemia (CLL). B-PLL is an extremely rare disease. Less than 1 percent of the B cell leukemias has been found to be B-PLL.¹

B-PLL might have similar clinical findings with some other leukemia forms. T-PLL, CLL, hairy-cell leukemia variant (HCL-V), splenic marginal zone lymphoma (SMZL) and mantle cell lymphoma (MCL) are the most possible differential diagnostic diseases of B-PLL. Clinical discrimination of each disease is important due to the differences in treatment approaches and overall survival. Peripheral blood (PB) smear, flow cytometry, bone marrow (BM) biopsy, and imaging help to reach the right diagnosis.² Hereby, we report a 80 year old woman presenting with fatigue, leucocytosis and mild anemia.

Case Report

A 80-year-old woman presented to the emergency service with fatigue. She did not have any other known chronic diseases. Physical presentation revealed 2 cm palpable enlarged spleen below the costal margin, bilateral small cervical lymph nodes and no hepatomegaly. Her hemoglobin level was 11.2 (12-18) g/dL, platelet count was 260.000 (130000-400.000)/µL, white blood cell count was 115.000/µL (4.200-11.000), neutrophil count was 7780 (1900-8000)/µL, lymphocyte count was 25.440 (0.9-5.200)/µL and LUC (large unstained cells) count was 81.200 (0-0.5)/µL. Her blood chemistry was unremarkable, except for a lactate dehydrogenase level of 243 (125-220) U/L, and beta-2 microglobulin level of 5.3 mg/L (0.7-1.8). Peripheral blood smear evaluation showed 85% prolymphocytes with moderately condensed nuclear chromatin, prominent nucleoli, and a faintly basophilic cytoplasm (Figure 1). She had no monoclonal gammapathy in the serum and urine immunoelectrophoresis. PET-CT showed mediastinal lymph nodes with cervical lymph nodes. And the greatest size of mediastinal lymph nodes was 20×12 mm and cervical lymph nodes was 8×13 mm. There was no pathological FDG involvement in the spleen. BM aspiration smear exhibited atypical wide lymphocytes with prominent nucleoli and abundant agranular cytoplasm (Figure 2). There were no cyttoplasmic projections such as hairy projections or blebbings on the cell surface of the atypical lymphocytes (Figures 1 and 2).

Flow cytometry analysis revealed CD34 negative lymphocytes. Lymphocytes had negative CD33⁺, CD13⁺, CD117⁺, CD23⁺, FMC7⁺, MPO⁺, CD15⁺, CD14⁺, CD64⁺. And lymphocytes had positive CD5⁺, CD19⁺, CD20⁺, CD22⁺, CD11c⁺, CD25⁺, CD79a⁺ and CD79b⁺. Fluorescence in situ hybridization (FISH) technique analysis reveals no translocation between the 11th and 14th chromosome. BM biopsy revealed interstitially distributed atypical cells with wide nucleus and prominent nucleolus (Figure 3). Immunohistochemical staining of the atypical cells showed diffuse CD20⁺, PAX5, CD5, BCL2 positivity and partial CD23 strong positivity (Figure 4). TDT, CD10, CD34, CD117, BCL1, BCL6, SOX11 and Annexin were not detected on the atypical cells. Besides, CD25 was weakly and non-specifically detected by staining. Lower rate of lymphocytes with small size were detected to have CD3 by staining. Lastly, reticulin fiber was not increased (grade 0/3). BM biopsy was reported as primarily compatible with prolymphocytic leukemia for the diagnosis.

Discussion

B-PLL is a very rare disease. And it might not be kept in mind especially in the patients with the presentation of clinically similar features sharing diseases. Discrimination of B-PLL from the other cli-
nically similar features sharing diseases are important because of the different treatment approaches and different follow-up programs. The best first line treatment for T-PLL is alemtuzumab. Alemtuzumab could also be used in B-PLL. Fludarabine, cyclophosphamide and rituximab could also be used as part of other effective chemotherapy regimens for the treatment of B-PLL. Morphology, flow cytometric analysis and pathology help to put the accurate diagnosis. Unlike B-PLL, T-PLL cells have T cell markers detected by flow cytometry. Lymphocytes of our patient had CD19+ and CD20+ on flow cytometric analysis. And this feature of flow cytometric analysis made us far from the diagnosis of T-PLL. HCL-V cells usually lack CD25+ on the cell. But flow cytometric analysis of our patient showed strong positivity for CD25+. And immunohistochemical staining of the atypical cells of our patient also showed weakly and non-specifically staining for CD25. Besides, atypical cells of our patient did not have cytoplasmic projections. So that, our patient’s clinical findings are not suitable for the diagnosis of HCL-V.

SMZL is a rare indolent B-cell lymphoma involving spleen, BM, and frequently the blood. Peripheral blood atypical lymphocyte morphology consists of villous lymphocytes with basophilic cytoplasm. Franco et al. reported that bone marrow (BM) infiltration of the SMZL was mostly of the intrasinusoidal type and BM infiltration tended to become frankly nodular after splenectomy. On the other side, atypical neoplastic lymphocytes of our patient did not have villous projections. And our patient did not have massive splenomegaly and pathological splenic FDG involvement. The pathological infiltration of the BM in our patient was interstitial unlike the sinusoidal infiltration tendency of the SMZL. Besides, FISH technique analysis of our patient was negative for t(11;14). BCL1 was not detected on the atypical cells taken by the biopsy. These findings also exclude the diagnosis of MCL.

Conclusions

In conclusion, we should think of B-PLL in case of high circulating prolymphocyte counts with prominent nucleoli and without villous projections in the peripheral smear. And we should also keep in mind some other clinically similar features sharing disorders such as SMZL, HCL-Variant T-PLL in the differential diagnosis. Lastly, morphology and flow cytometry analysis will help to make the accurate diagnosis.

References

1. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008;19:379.
2. Dearden C. How I treat prolymphocytic leukemia. Blood 2012;120:538-51.
3. Chaar BT, Petruska PJ. Complete response to alemtuzumab in a patient with B prolymphocytic leukaemia. Am J Hematol 2007;82:417.
4. Bowen AL, Zomas A, Emmett E, et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia Br J Haematol 1997;96:617-9.
5. Sibbald R, Catovsky D. Complete remission in prolymphocytic leukaemia with the combination chemotherapy CHOP. Br J Haematol 1979;42:488-90.
6. Herold M, Spohn C, Schlag R, et al. Fludarabine/cyclophosphamide chemotherapy for B-prolymphocytic leukaemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2003;102. Abstract 2499.
7. Chow KU, Kim SZ, von Neuhoff N, et al. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol 2011;87:426-33.
8. Robak T. Hairy-cell leukaemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011;37:3-10.
9. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leuke-
10. Cessna MH, Hartung L, Tripp S, et al. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol 2005;123:132-8.
11. Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood 2016;127:2072-81.
12. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 2008;111:2253–60.
13. Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001;91:294-301.